NovalGen
Amit Nathwani is a highly experienced individual who currently serves as the Founder and CEO of NovalGen. Amit also holds the position of Professor of Haematology at UCL. Notably, Amit has been involved in groundbreaking AAV gene therapy developments for haemophilia B in collaboration with St. Jude Children's Research Hospital. Amit's contributions have paved the way for effective gene therapy treatments for haemophilia A and have been licensed to companies like UniQure Therapeutics and BioMarin. In addition, Amit Nathwani is a founding member and Chief Scientific Officer of Freeline Therapeutics.
This person is not in any teams
NovalGen
NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond